Tolvaptan: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett (→Uses) |
imported>Gareth Leng No edit summary |
||
| Line 1: | Line 1: | ||
{{subpages}} | |||
==Uses== | ==Uses== | ||
Tolvaptan can be used for euvolemic or hypervolemic [[hyponatremia]].<ref name="pmid20538391">{{cite journal| author=Rozen-Zvi B, Yahav D, Gheorghiade M, Korzets A, Leibovici L, Gafter U| title=Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis. | journal=Am J Kidney Dis | year= 2010 | volume= 56 | issue= 2 | pages= 325-37 | pmid=20538391 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20538391 | doi=10.1053/j.ajkd.2010.01.013 }}</ref><ref name="pmid17105757">{{cite journal| author=Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS et al.| title=Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. | journal=N Engl J Med | year= 2006 | volume= 355 | issue= 20 | pages= 2099-112 | pmid=17105757 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=17105757 | doi=10.1056/NEJMoa065181 }} </ref><ref>(2009) [http://www.medicalletter.org/restricted/articles/w1326c.html Tolvaptan (Samsca) for Hyponatremia] The Medical Letter</ref> However, [[vasopressin]] receptor antagonist may increase the frequency of rapid sodium correction although [[osmotic demyelination syndrome]] may not be increased.<ref name="pmid20538391"/> | Tolvaptan can be used for euvolemic or hypervolemic [[hyponatremia]].<ref name="pmid20538391">{{cite journal| author=Rozen-Zvi B, Yahav D, Gheorghiade M, Korzets A, Leibovici L, Gafter U| title=Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis. | journal=Am J Kidney Dis | year= 2010 | volume= 56 | issue= 2 | pages= 325-37 | pmid=20538391 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20538391 | doi=10.1053/j.ajkd.2010.01.013 }}</ref><ref name="pmid17105757">{{cite journal| author=Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS et al.| title=Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. | journal=N Engl J Med | year= 2006 | volume= 355 | issue= 20 | pages= 2099-112 | pmid=17105757 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=17105757 | doi=10.1056/NEJMoa065181 }} </ref><ref>(2009) [http://www.medicalletter.org/restricted/articles/w1326c.html Tolvaptan (Samsca) for Hyponatremia] The Medical Letter</ref> However, [[vasopressin]] receptor antagonist may increase the frequency of rapid sodium correction although [[osmotic demyelination syndrome]] may not be increased.<ref name="pmid20538391"/> | ||
Latest revision as of 10:20, 17 October 2010
Uses
Tolvaptan can be used for euvolemic or hypervolemic hyponatremia.[1][2][3] However, vasopressin receptor antagonist may increase the frequency of rapid sodium correction although osmotic demyelination syndrome may not be increased.[1]
Tolvaptan can be used for heart failure.[4][5]
References
- ↑ 1.0 1.1 Rozen-Zvi B, Yahav D, Gheorghiade M, Korzets A, Leibovici L, Gafter U (2010). "Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis.". Am J Kidney Dis 56 (2): 325-37. DOI:10.1053/j.ajkd.2010.01.013. PMID 20538391. Research Blogging.
- ↑ Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS et al. (2006). "Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.". N Engl J Med 355 (20): 2099-112. DOI:10.1056/NEJMoa065181. PMID 17105757. Research Blogging.
- ↑ (2009) Tolvaptan (Samsca) for Hyponatremia The Medical Letter
- ↑ Gheorghiade M, Konstam MA, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K et al. (2007). "Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.". JAMA 297 (12): 1332-43. DOI:10.1001/jama.297.12.1332. PMID 17384438. Research Blogging.
- ↑ Konstam MA, Gheorghiade M, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K et al. (2007). "Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.". JAMA 297 (12): 1319-31. DOI:10.1001/jama.297.12.1319. PMID 17384437. Research Blogging.